LCLi Chen

Li Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li Chen has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification and Characterization of EmNag, a Novel β-1,2-N-Acetylglucosaminidase from Elizabethkingia meningoseptica

    by Shaoxian Lyu, Yongliang Tong, Qiange Lin, Yilin Ye, Xinliu Geng, Cuiying Chen, Xinrong Lu, Guiqin Sun, Li Chen

    N-Acetylglucosamine exists in various glycoforms and linkage patterns within organisms, playing a crucial role in numerous vital biological processes. The signal of β-1,2-N-acetylglucosamine is a key component within complex biantennary N-glycans on the cell surface, leaving related research in its early exploratory stages. Currently, there is a lack of efficient tools and methods capable of directly modifying terminal N-acetylglucosamine on living cells. In this study, we identified a novel β-N-acetylglucosaminidase from Elizabethkingia meningoseptica FMS-007, which specifically cleaves nonreducing terminal β-1,2-N-acetylglucosamine, enabling direct removal from native glycoproteins and/or free oligosaccharides. More importantly, we demonstrate for the first time the successful removal of β-1,2-N-acetylglucosamine from the living cell surface using this enzyme. Based on its isolation and newly characterized cell-surface glycan-editing activity, we designated it as EmNag, also termed cell-surface glycan-editing N-acetylglucosaminidase (csgeNag). It showed favorable enzymatic stability between pH 5–8 and from 4 to 37 °C. Sequence analysis and alanine-scanning mutagenesis identified a conserved active pocket containing the catalytic residue pair Asp317-Glu318, with Asp317 being essential for activity. In summary, our findings provide an effective and reliable method for the targeted removal of β-1,2-N-acetylglucosamine from the living cell surface, establishing a foundation for further functional studies and practical applications.

  • Open Access

    Deglycosylation at War: Host N-Glycoprotein Remodeling in Infection and Immunity

    by Xin Qian, Jianjun Wang, Yuxin Zhang, Qiange Lin, Yilin Ye, Junyou Lin, Xinrong Lu, Shuying Yuan, Li Chen, Guiqin Sun

    N-glycan remodeling, including the hydrolysis of both glycopeptide linkages and glycosidic linkages, serves as a critical regulatory mechanism in biological processes including molecular recognition and immune responses. Growing evidence reveals that the dynamic balance between host protein glycosylation and N-glycan remodeling significantly influences the outcomes of infectious diseases. During infection, host N-glycoproteins remodeling can be driven either by the host as a defense strategy or by pathogens as an offensive mechanism. This review systematically examines how both host- and pathogen-induced N-glycan remodelling events affect infection outcomes. We highlight the dual functionality: host-driven remodeling often enhances immune recognition and pathogen clearance, whereas pathogen-driven remodeling facilitates adhesion, immune evasion, and nutrient acquisition. By integrating evidence from direct enzymatic N-glycan remodeling and indirect glycan-processing models, this review offers a novel perspective on glycan-mediated microbial-host interactions, highlighting how targeted modulation of these processes may advance therapeutic strategies against infectious diseases.

  • Open Access

    Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics

    by Qiange Lin, Yuxin Zhang, Junyou Lin, Yilin Ye, Xin Qian, Xinrong Lu, Shaoxian Lyu, Xinliu Geng, Li Chen, Guiqin Sun

    Aspartylglucosaminidase (AGA) is an amidohydrolase that can hydrolyze the amide bond between N-acetylglucosamine (GlcNAc) and asparagine (Asn), producing N-acetylglucosamine and aspartic acid (Asp). AGA is distributed in both eukaryotes and prokaryotes. In this study, we identified the sequence of AGA in Elizabethkingia meningoseptica (EmAGA), cloned and expressed it in Escherichia coli, and recharacterized its properties, confirming its substrates as aspartylglucosamine (Asn-GlcNAc) and Asn. Key residues affecting its enzymatic activity were predicted through molecular docking and conserved site analysis, and 10 key residues that affected enzymatic activity were verified, eight of which regulated activity by interfering with EmAGA’s autoproteolysis, indicating that autoproteolytic cleavage into α/β subunits was essential for EmAGA maturation. Molecular dynamics simulations were performed on autohydrolysis-impaired mutants, which showed a more stable conformation and lower energy. In summary, EmAGA’s functional characterization provided novel evidence for elucidating its molecular mechanism. Clinically used Asparaginase (ASNase) exerts its therapeutic effect on acute lymphoblastic leukemia (ALL) through its asparaginase activity, but it is limited by glutamine off-target side effects, while EmAGA also has asparaginase activity but no glutaminase activity, rendering its potential as a basis for novel anti-leukemic enzymatic therapeutics.

  • Open Access

    Maternal and neonatal outcomes in obstetric antiphospholipid syndrome: a retrospective case-control study

    by Lin Rao, Jia Lu, Hong Li, Liang Xu, Dongjian Yang, Wendong Han, Li Chen

    Objective: The combination of low-dose aspirin (LDA) and low-molecular-weight heparin (LMWH) is the standard of care for obstetric antiphospholipid syndrome (OAPS), significantly improving live birth rates. However, whether this regimen fully normalizes the pregnancy course and mitigates risks for both the mother and the neonate remains unclear. This study aimed to systematically evaluate whether significant maternal and neonatal morbidity persists in OAPS patients despite successful treatment and live birth. Methods: This retrospective cohort study included 256 OAPS patients, including 166 criteria OAPS patients (C-OAPS—patients who fulfilled both the clinical and laboratory criteria of the Sydney criteria) and 90 non-criteria OAPS patients (NC-OAPS—patients who fulfilled only the clinical or only the laboratory criteria of the Sydney criteria) who achieved live birth, along with 768 matched healthy controls. We compared basic characteristics, laboratory parameters, and perinatal outcomes between the groups. Results: Compared to healthy controls ( n = 768), treated OAPS patients ( n = 256) exhibited a persistent hypercoagulable state (elevated D-dimer and fibrin degradation product (FDP), p < 0.01) and a higher incidence of anemia ( p < 0.001). Their neonates had significantly lower birth weight ( p = 0.006) and elevated risks of neonatal infection (adjusted OR = 3.12, p = 0.004) and hyperbilirubinemia (adjusted OR = 2.06, p = 0.024), with the infection risk remaining significant in full-term infants. A subgroup analysis revealed no significant differences in obstetric history, maternal complications, comorbidities, and outcomes between the C-OAPS and NC-OAPS groups. Conclusion: Despite standard treatment, OAPS patients who deliver successfully remain at an increased risk for persistent maternal hypercoagulability and adverse neonatal outcomes. These findings underscore the need for a paradigm shift in management—from merely ensuring live birth to safeguarding neonatal health through proactive, multidisciplinary perinatal care.


  • Open Access

    Downregulation of Endo-Beta-N-Acetylglucosaminidase in Caenorhabditis elegans Improves Stress Adaptivity

    by Xinrong Lu, Yongliang Tong, Mengting Wu, Shaoxian Lyu, Jiale Fan, Junyu Zheng, Lin Zou, Danfeng Shen, Lin Rao, Linlin Hou, et al.

    Introduction: Endo-beta-N-acetylglucosaminidase (ENGASE) is one of the key enzymes involved in the structural and functional regulations of glycoproteins. Although its enzymatic activities and applications have been well studied in vitro, its biological function in vivo yet remains to be illustrated. In this study, the biological function of ENGASE in Caenorhabditis elegans was explored in detail. Methods: An Engase gene knockout in C. elegans (CeEng-1 or CeEngase) was constructed and subjected to a panel of phenotypical and glycomics analysis. In addition, in vitro and in vivo ENGASE inhibition assays were performed. Results: Engase knockout worm’s adaptivity to environmental stresses (heat and osmotic) was significantly improved, and its longevity was also increased mildly. A clustered change in basement membrane proteins (e.g., LAM-1, LAM-2, and EPI-1) was illustrated by N-glycopeptide analysis, suggesting that ENGASE is involved in a basement membrane-based stress regulation. Then, the heat stress phenotype was further supported by in vivo CeEngase knockdown assay and in vitro and in vivo small compound inhibitory assay of CeENGASE, indicating that ENGASE is a potential drug target for stress management. Conclusion: Engase is actively involved in a basement membrane-mediated stress adaptation and could serve as a potential target for healthcare products.


  • A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by C-type lectin pathway-mediated tumor associated macrophages repolarizing

    by Yongliang Tong, Runqiu Chen, Xinrong Lu, Cuiying Chen, Guiqin Sun, Xiaolu Yu, Shaoxian Lyu, Meiqing Feng, Yiru Long, Likun Gong, et al.


  • Open Access

    Down regulation of Engase in Caenorhabditis elegans may improve its stresses adaptivity

    by Xinrong Lu, Yongliang Tong, Mengting Wu, Shaoxian Lyu, Jiale Fan, Junyu Zheng, Lin Zou, Danfeng Shen, Lin Rao, Linlin Hou, et al.

    Endo-beta-N-acetylglucosaminidase (ENGASE) is one of the key enzymes involved in the regulation of structure and function of glycoproteins. It is conserved from prokaryotic to eukaryotic cells. Although their activities in vitro and applications have been well studied, the biological function of ENGASE remains to be illustrated. In this study, we analyzed the molecular and physiological function of Engase from Caenorhabditis elegans homolog eng-1 ( CeEngase ). We found that CeEngase knockout or knockdown increased the environmental stresses adaptability, such as heat stress and osmotic stress. Preliminary glycomics analysis showed that the basement membrane proteins of extracellular matrix may be the main targets of CeENGASE. In addition, CeENGASE may selectively prefer to N2H7 glycans on glycoproteins. In conclusion, our data illustrated that the defection and/or down regulation of CeEngase may provide a beneficially adaptation for stresses.

  • Open Access

    A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by affecting tumor associated macrophages

    by Yongliang Tong, Runqiu Chen, Xinrong Lu, Cuiying Chen, Guiqin Sun, Xiaolu Yu, Shaoxian Lyu, Meiqing Feng, Yiru Long, Likun Gong, et al.

    Cancer cells employ various mechanisms to evade immune surveillance. Their surface features, including a protective “sugar coat” and immune checkpoints like PD-L1 (programmed death ligand 1), can impede immune cell recognition. Sialic acids, which carry negative charges, may hinder cell contact through electrostatic repulsion, while PD-L1 transmits immunosuppressive signals to T cells. Furthermore, cancer cells manipulate macrophages within the tumor microenvironment to facilitate immune escape. Prior research has demonstrated the effectiveness of separately blocking the PD-L1 and sialic acid pathways in eliciting anti-tumor effects. In this study, we investigated the relationship between PD-L1 expression and genes associated with sialic acid in clinical databases. Subsequently, we developed a novel nanobody enzyme fusion protein termed Nb16-Sia to simultaneously target both PD-L1 and sialic acid pathways. In vivo experiments confirmed the anti-tumor activity of Nb16-Sia and highlighted its dependence on macrophages. Further investigations revealed that Nb16-Sia could polarize macrophages towards the M1 phenotype through the C-type lectin pathway in vitro and eliminate tumor-associated macrophages in vivo. In conclusion, our findings demonstrate that the fusion of PD-L1 nanobody with sialidase effectively targets tumor-associated macrophages, resulting in significant anti-tumor effects. This approach holds promise for drug development aimed at enhancing immune responses against cancer.